Gastrointestinal Stromal Tumors
Oncology·MeSH: Gastrointestinal Stromal Tumors
Prevalence
30.0 / 100K
4 drugs in development·2 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| Bezuclastinib | Cogent Biosciences, Inc. (COGT) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| THE-630 | Theseus Pharmaceuticals, Inc. (THRX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Gastrointestinal Stromal Tumors?
BioSniper tracks 4 drugs in development for Gastrointestinal Stromal Tumors across 2 companies.
How many clinical trials target Gastrointestinal Stromal Tumors?
There are 3 clinical trials targeting Gastrointestinal Stromal Tumors tracked by BioSniper.
What is the prevalence of Gastrointestinal Stromal Tumors?
The estimated prevalence of Gastrointestinal Stromal Tumors is approximately 30.0 per 100,000 population.
Deep-dive into Gastrointestinal Stromal Tumors
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis